Panbela Therapeutics Inc. (PBLA) to Acquire Cancer Prevention Pharmaceuticals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil rises as renewed US-Iran strikes stoke supply fears
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
February 22, 2022 8:00 AM ESTCreates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs
Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestonesAcquired lead asset will begin a fully-funded registration trial anticipated to start by year-end
MINNEAPOLIS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today announced it has entered into a definitive agreement to acquire Cancer Prevention... More
